US House Cosmetics Hearing: Preemption, FDA Ingredient Review Could Be Regulatory Reform Snags
Federal preemption of state and local requirements that differ from federal mandates came up repeatedly at the House Energy & Commerce Health Subcommittee’s 4 December cosmetics hearing. Meanwhile, both NGO and industry stakeholders generally support FDA review of cosmetic ingredients, but the details of such a framework likely will be contentious as work progresses.
You may also be interested in...
No one is saying that it will, but the Independent Cosmetic Manufacturers and Distributors is concerned that it might. The trade group is surveying its members and wider industry on COVID-19 challenges and future prospects in order to represent their interests in Washington and dissuade “uninformed cosmetics legislation.”
In a pause from the trade group’s 2020 annual meeting in Palm Beach, FL, PCPC senior executives spoke with HBW Insight about legislative priorities and challenges at the federal and state levels, emerging microplastic regulations and whether industry and consumers have a “trust problem.”
Approved by the House Energy and Commerce Health Subcommittee on 11 March, H.R. 5279 still lacks any concrete provisions regarding federal preemption of state and local requirements, though bill author and full committee chair Frank Pallone, D-NJ, remains committed to discussions on the subject. He recognized preemption as “a major issue that I know we have to deal with.”